Pharmaceutical giants Bayer and Janssen have been accused of trying to undermine the Xarelto bellwether litigation process by limiting early trial candidates to only a handful of states.
The plaintiff group has recently accused the drug manufacturers of proposing a “truly unprecedented” idea, which would restrict the bellwether selections to Louisiana, Mississippi, and Texas.
While the companies agree that the Xarelto bleeding lawsuits should be categorized, both parties argue over the geographical locations of the districts each case is filed in. As of now the companies disagree with the lawsuits chosen going before juries, because they are from different districts then from where the companies’ headquarters are located.
According to the proposal from Bayer and Janssen, the companies name a specific amount of Xarelto lawsuits per designated state. More specifically the companies are calling for half of the bellwether trials to come from Louisiana, six from Mississippi, two from Texas, and 12 from other states.
Half of the specific geographic districts cases would be selected at random, with each competing party selecting a quarter of those cases that are also based on geographical location.
The plaintiffs responded by stating that the companies were impairing the selection process of the cases, and are basically “cherry picking” which Xarelto lawsuits they want.
The companies countered in a separate filing that their proposal would adhere to the multidistrict litigation (MDL) as envisioned by the presiding judge, U.S. District Judge Eldon Fallon of the Eastern District of Louisiana.
Xarelto Bellwether Trial Status
In a previous proposal from the plaintiffs, they are requesting the Court to conduct a census of claims first so they can be sorted into categories that are representative of typical Xarelto injury cases.
Then the plaintiffs and defendants would then select their respective Xarelto injury claims based on said categories, with at least two of their 10 cases coming from the Eastern District of Louisiana.
Judge Fallon had previously ordered the parties to propose a selection process for the pool of 40 bellwether Xarelto lawsuits, as part of the coordinated pretrial proceedings. Each of the selected cases will go through a specific discovery process, to prepare for a series of early trial dates that are expected to begin with Aug. 01, 2016.
Xarelto Bleeding Allegations
Xarelto is a popularly prescribed anticoagulant manufactured jointly between Bayer and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, and is meant to be a direct competitor against other new generation anticoagulants and Warfarin. The blood thinner is used to prevent strokes in patients who undergo hip or knee replacement surgery as well as treat or reduce the recurrence of deep vein thrombosis and pulmonary embolism.
Unfortunately Xarelto and other new generation anticoagulants have been accused of causing internal bleeding injuries, including life-threatening gastrointestinal bleeding, hemmorhagic strokes, and brain hemorrhages.
Many injured patients have filed Xarelto lawsuits alleging the drug manufacturers ailing to warn consumers that Xarelto does not have an antidote, leaving doctors without any effective means to treat and stabilize patients who experienced uncontrolled and excessive bleeding.
Ever since the Xarelto MDL was established in December 2014 the number of cases filed has grown dramatically. Six months after its establishment, in June 2015, there were approximately 500 lawsuits filed in the MDL. Court documents show that currently there are about 1,200 lawsuits filed in the MDL and that number is expected to continually rise as litigation continues.
The Xarelto MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
Get Help – It’s Free
Join a Free Xarelto Class Action Lawsuit Investigation
If you or a loved one took Xarelto (rivaroxaban) and suffered injuries such as uncontrollable internal bleeding, gastrointestinal bleeding, hemorrhaging, deep vein thrombosis or pulmonary embolism, you may have a legal claim. See if you qualify by filling out the short form below.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- Which blood thinner did you or a loved one take at the time of the injury or injuries?*
- Pradaxa
- Xarelto
- Unknown
- Other
- Please check the injuries suffered:*
-
Death
-
Gastrointestinal Bleeding
-
Other Internal Bleeding
-
Cerebral Hemorrhaging
-
Ischemic Stroke
-
Unsure
-
None
-
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.*
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 35) {gformInitChosenFields(‘#input_35_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_35_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_35_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [35, 1]) } );
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2015 Top Class Actions® LLC
Various Trademarks held by their respective owners
The post Xarelto MDL: Drug Makers Attempt Geographic Limitations appeared first on Top Class Actions.
No comments:
Post a Comment